OmanDocSign in

Curriculum · Metabolic and Endocrine and Diabetes Mellitus

Type 2 diabetes mellitus

What it is

Diabetes is classified into four main categories: type 1 diabetes, type 2 diabetes, gestational diabetes mellitus (diabetes diagnosed in the second or third trimester of pregnancy that was not clearly overt diabetes prior to gestation), and specific types of diabetes. Type 2 diabetes accounts for 90% of cases. It is characterized by:

How it is treated

Metformin is the first medication prescribed when an oral agent is required, and first-line therapy to reduce microvascular complications, assist in weight management, reduce the risk of cardiovascular events, and reduce mortality. It reduces glycemic levels, is linked to weight loss and fewer occurrences of hypoglycemia, and is less expensive than most other options. It decreases food intake by about 250-300 kcal per day and gives moderate weight loss in the range of 2-4 kg. If more than one agent is required, metformin is continued and one or more of the following is added: a sulfonylurea such as glipizide, a thiazolidinedione such as pioglitazone, an SGLT2 inhibitor such as empagliflozin, or a DPP-4 inhibitor such as alogliptin. Weight is part of that choice. Sulfonylureas, including glimepiride, are associated with weight gain. Empagliflozin, liraglutide, metformin and sitagliptin are not, and SGLT2 inhibitors and GLP1 agonists give clinically significant weight loss. A patient who is intolerant of metformin is unlikely to be successful with a third trial of that agent; empagliflozin is then a second-line choice. Sitagliptin and liraglutide should be avoided or used with caution after pancreatitis.

How the control is measured is set out with the same care as what is given. The HbA1C test is the most important test for assessment of glycemic control; it should be done at diagnosis, and during follow up every 6 months if glycemia is controlled and stable, or every 3 months if therapy has been changed or the glycemic target is not met. So a woman whose therapy has not been changed and whose HbA1c is at target is seen at 6 months, not at 3. For most non-pregnant adults the target is an HbA1C below 7.0%, made more or less stringent according to hypoglycemia risk, disease duration, life expectancy, important comorbidities, established vascular complications, patient preference and resources. The two ends it moves between are a more stringent A1C <6.5% and a less stringent A1C <8%, and every factor has a direction: hypoglycemia risk low against High; disease duration Newly diagnosed against Long standing; life expectancy Long against short; important comorbidities Absent against Severe; established vascular complications Absent against Severe; patient preference Highly motivated against Not motivated; resources Readily available against Limited.

In a child or adolescent with type 2 diabetes the comorbidities are checked at set times. Urine ACR should be obtained at the time of diagnosis and annually, an elevated ACR above 30 mg/g creatinine confirmed on two of three samples; blood pressure is monitored at every visit; retinal examination is performed at diagnosis and annually thereafter; and ALT and AST are measured at diagnosis and annually thereafter to evaluate for NAFLD and non-alcoholic Steatohepatitis. Testing for dyslipidemia is the one item that runs on a different clock: it is repeated once glycemic control has been achieved or after 3 months of initiation of medication, and annually thereafter.

When insulin is started is set out as a list, and it is not only the end of the road. Insulin is for all T1DM, and it is considered for T2DM at any stage of the disease if there is ongoing catabolism, meaning unintentional weight loss; if severe symptoms of hyperglycemia are present; if the HbA1C level is above 10% or the blood glucose readings are very high; or if glycemic targets are not achieved with the other anti-hyperglycemic medications. So a patient with unintentional weight loss, or one sitting above 10%, is put on insulin even while the other medications continue.

The classes are worth holding as one table, by mechanism, route and main side effect.

In pregnancy the two that are used together are named. A 30 year old G2P1 woman with a history of type 2 diabetes mellitus at 40 weeks, managing her diabetes on a regimen of metformin and insulin, with good glycemic control and HbA1c maintained below 6.5%, and an estimated fetal weight of 4200 grams on the last ultrasound, is the setting in which the mode and timing of delivery are then weighed.

What can go wrong

Renal function is a limit on metformin. It was once contraindicated at a creatinine of 1.5 mg/dL in men and 1.4 mg/dL in women, but it is now permitted with an eGFR between 45 and 60 mL/min/1.73 m2. It should not be used below 45 mL/min/1.73 m2, where lactic acidosis is more likely. Hypoglycemia in the elderly is the other drug harm. Glyburide carries a risk of prolonged hypoglycemia and is listed on the Beers Criteria, which are the American Geriatrics Society list of potentially inappropriate medication use in older adults of 65 years of age or more, and the drugs put on it here are: 1) glyburide, for prolonged hypoglycemia; 2) amitriptyline, imipramine and paroxetine, highly anticholinergic and sedating and able to cause orthostatic hypotension; 3) donepezil, to be avoided in patients with syncope because of an increased risk of bradycardia; and major hypoglycemic events have been associated with a greater risk of dementia. A hemoglobin A1c of 6.1% correlates with an estimated average glucose of 128 mg/dL, which in an elderly patient is a warning rather than a success. The hyperglycaemic emergency of type 2 diabetes is the hyperosmolar hyperglycaemic state: there is still some insulin available, so there is minimal or no ketone formation, and it develops insidiously over days with more extreme volume depletion. Its mortality rate is relatively higher than that of diabetic ketoacidosis. It presents with fatigue, altered level of consciousness, hyperviscosity, which increases the risk for MI and stroke, and hypotension. The three diagnostic criteria are:

  1. Hypovolaemia
  2. Marked hyperglycaemia (>30 mmol/L) without significant ketonuria or acidosis
  3. Significantly raised serum osmolality (>320 mosmol/kg)

Management is to normalise the osmolality gradually, replace fluid and electrolyte, and give no insulin unless there is significant ketonuria or acidosis; in clinical practice the majority of these patients present with mild concurrent ketosis or acidosis, or are very unwell with poor intake, so that they require insulin anyway to correct the biochemical deficits. The complications are MI, stroke and peripheral arterial thrombosis, and rarely seizure, cerebral oedema and central pontine myelinolysis. Diabetes is also a risk for malignant (necrotising) otitis externa, where pain is unrelenting despite strong analgesia. It needs urgent ENT assessment and long courses of intravenous antibiotics, and at an advanced stage it can cause ipsilateral facial nerve palsy.

Repeated hypoglycemia is a reason to change the treatment, not only to counsel about it. The most important step in the management of hypoglycemia is to identify the cause in order to prevent future episodes, and if there are no dietary factors and no change in lifestyle, then the anti-diabetic medications, insulin doses and glycemic goals should be reviewed and possibly modified. A patient who knows her own episodes and treats them has not been made safe by that; the drug and the goal are what change.

Fasting in Ramadan does not stop the drugs; it moves and trims them, and the table is worth holding drug by drug. Metformin prolonged release once daily and metformin immediate release once daily keep the same daily dose and are taken at iftar; twice daily is taken at iftar and suhoor; three times daily takes the morning dose at suhoor and combines the afternoon and evening dose at iftar. Pioglitazone keeps its dose and can be taken with iftar or suhoor. The glinides, repaglinide and nateglinide, and the alpha glucosidase inhibitors, acarbose, voglibose and miglitol, all come down from three doses to two, one with iftar and one with suhoor. Of the DPP-4 inhibitors, sitagliptin 100 mg once daily and linagliptin 5 mg once daily keep the same dose and are taken with iftar, while vildagliptin 50 mg twice daily is taken with iftar and suhoor. Liraglutide needs no dose modification once appropriate dose titration has been achieved prior to Ramadan, 6 weeks before. The sulfonylureas, with glibenclamide avoided, are decreased if glycaemic control is good: gliclazide MR once daily and glimepiride once daily are taken with iftar, and gliclazide twice daily with iftar and suhoor, its suhoor dose being the one that may come down.

The SGLT2 inhibitors are the row with more than a dose in it. Their dose is not changed and they are taken with iftar, but increased fluid intake is advised, and they are to be avoided in the elderly, in renal impairment, in hypotension, or where diuretics are being used. So of everything a fasting patient may be on, it is the SGLT2 inhibitor that is the risk in an older patient or one already taking a diuretic.